Back to Stocks

STXS

Stereotaxis, Inc.
2 filings tracked
healthcaremedical devicesSMALL ($300M-2B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Stereotaxis is evolving from a niche magnetic navigation provider into a comprehensive robotic intervention platform. The cornerstone of this transformation is the acquisition of Robocath, which integrates advanced mechanical robotics into the company's portfolio.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a robotic renaissance, Stereotaxis' core financials show signs of systemic weakness. Total revenue fell 16% year-over-year to $6.3 million, and the operating loss widened to nearly $6 million for the quarter.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every STXS filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company at a critical inflection point, balancing a bold strategic expansion against a deteriorating short-term financial profile. The acquisition of Robocath and the receipt of FDA 510(k) clearances for the GenesisX Synchrony platform provide a legitimate catalyst for long-term growth. However, these milestones are juxtaposed against a 16% decline in quarterly revenue and a persistent reliance on capital markets to fund operations. Investors are essentially betting on whether the multi-modal robotics strategy can scale fast enough to outpace the current cash burn and revenue contraction. While the margin expansion is a positive signal of internal discipline, the external environment—characterized by tariff uncertainties and hospital budget constraints—remains a significant headwind. The overall impact of the filing is a shift in the investment thesis from a pure-play magnetic navigation bet to a broader, higher-risk play on the digitization and robotization of the entire interventional laboratory.

Selected Quarter

Core Takeaway

Stereotaxis is diversifying its technology base to enter neuro and coronary markets, though it must overcome declining quarterly revenues and high operational burn.

Investor Lens

The trade-off is between the long-term potential of a diversified robotic platform and the immediate risk of further dilution and cash depletion.

Watch Next

Integration milestones of Robocath and the impact of new 10% import tariffs on cost of goods sold.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.17Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 13

Revenue declined 16% year-over-year to $6.3 million.

earnings miss
70%
bullishMay 13

Gross margins improved by 600 basis points to 60.3%.

margin expansion
60%
bullishMay 13

Acquisition of Robocath to expand into neuro and coronary robotic interventions.

acquisition
80%
neutralMay 13

Raised $4.6 million net through ATM offering to support operations.

capital raise
50%
bearishMay 13

Revenue declined 16% year-over-year to $6.3 million.

earnings miss
70%
bullishMay 13

Gross margins improved by 600 basis points to 60.3%.

margin expansion
60%
bullishMay 13

Acquisition of Robocath to expand into neuro and coronary robotic interventions.

acquisition
80%
neutralMay 13

Raised $4.6 million net through ATM offering to support operations.

capital raise
50%

Filing History

10-QMay 13, 2026
Expand Sequence

The Q1 2026 filing presents a company at a critical inflection point, balancing a bold strategic expansion against a deteriorating short-term financial profile. The acquisition of Robocath and the receipt of FDA 510(k) clearances for the GenesisX Synchrony platform provide a legitimate catalyst for long-term growth. However, these milestones are juxtaposed against a 16% decline in quarterly revenue and a persistent reliance on capital markets to fund operations. Investors are essentially betting on whether the multi-modal robotics strategy can scale fast enough to outpace the current cash burn and revenue contraction. While the margin expansion is a positive signal of internal discipline, the external environment—characterized by tariff uncertainties and hospital budget constraints—remains a significant headwind. The overall impact of the filing is a shift in the investment thesis from a pure-play magnetic navigation bet to a broader, higher-risk play on the digitization and robotization of the entire interventional laboratory.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.